Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

作者:Takada Koji; Kashiwagi Shinichiro; Goto Wataru; Asano Yuka; Takahashi Katsuyuki; Takashima Tsutomu; Tomita Shuhei; Ohsawa Masahiko; Hirakawa Kosei; Ohira Masaichi
来源:Journal of Translational Medicine, 2018, 16(1): 86.
DOI:10.1186/s12967-018-1460-4